Factors Associated With Long-term Retention in Antiretroviral Therapy Among People Living With HIV: Evidence From a Tertiary Hospital in Jakarta, Indonesia

被引:0
|
作者
Mauleti, Ifael Yerosias [1 ]
Wibisana, Krishna Adi [1 ]
Syamsuridzal, Djati Prasetio [2 ]
Mulyati, Sri [2 ]
Lisdawati, Vivi [3 ]
Saptarini, Ika [4 ,5 ]
Nurhayati [4 ]
Hasugian, Armedy Ronny [4 ]
Hendarwan, Harimat [4 ]
机构
[1] Fatmawati Gen Hosp, Dept Internal Med, Jakarta, Indonesia
[2] Fatmawati Gen Hosp, Jakarta, Indonesia
[3] Fatmawati Gen Hosp, Directorate Human Resources Educ & Res, Jakarta, Indonesia
[4] Natl Res & Innovat Agcy, Res Ctr Preclin & Clin Med, Jalan Raya Jakarta Bogor, Bogor 16915, Indonesia
[5] Univ Indonesia, Doctoral Program Med Sci, Fac Med, Jakarta, Indonesia
来源
关键词
Human immunodeficiency virus; Acquired immune deficiency syndrome; Antiretroviral therapy; Retention; RISK-FACTORS; CARE; ADHERENCE; EFAVIRENZ; PROGRAMS;
D O I
10.3961/jpmph.23.512
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: This study investigated factors associated with the retention of people living with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) during the first 3 years of treatment. Methods: A retrospective study using electronic health records was conducted at a tertiary hospital in Jakarta, Indonesia. Adult HIVpositive patients who started ART from 2010 until 2020 were included. A binary logistic regression model was used to identify factors associated with ART retention in the first 3 years. Results: In total, 535 respondents were included in the analysis. The ART retention rates for the first, second, and third years were 83.7%, 79.1%, and 77.2%, respectively. The multivariate analysis revealed a negative association between CD4 count when starting ART and retention. Patients with CD4 counts >200 cells/mL were 0.65 times less likely to have good retention than those with CD4 counts <= 200 cells/mL. The year of starting ART was also significantly associated with retention. Patients who started ART in 2010-2013 or 2014-2016 were less likely to have good retention than those who started ART in 2017-2020, with adjusted odds ratios of 0.52 and 0.40, respectively. Patients who received efavirenz-based therapy were 1.69 times more likely to have good retention than those who received nevirapine (95% confidence interval, 1.05 to 2.72). Conclusions: Our study revealed a decline in ART retention in the third year. The CD4 count, year of enrollment, and an efavirenz-based regimen were significantly associated with retention. Patient engagement has long been a priority in HIV programs, with interventions being implemented to address this issue.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 50 条
  • [1] Prevalence and associated factors of depressive symptoms among people living with HIV on antiretroviral therapy in Jakarta, Indonesia
    Yunihastuti, Evy
    Lestari Agusin, Regina
    Sari, Vidya
    Jhariah Hidayah, Ainum
    Wulunggono, Wulunggono
    Pramukti, Hikmat
    Shinta, Mutiara
    Shatri, Hamzah
    Harjono Karjadi, Teguh
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2021, 26 (08) : 908 - 915
  • [2] Non-alcoholic fatty liver disease among people living with HIV on long-term antiretroviral therapy in Indonesia: Prevalence and related factors
    Pramukti, Hikmat
    Yunihastuti, Evy
    Gani, Rino A.
    Rinaldi, Ikhwan
    Hasan, Irsan
    Maria, Suzy
    SAGE OPEN MEDICINE, 2024, 12
  • [3] Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model
    Sivaporn Gatechompol
    Jiratchaya Sophonphan
    Sasiwimol Ubolyam
    Anchalee Avihingsanon
    Frank van Leth
    Frank Cobelens
    Stephen J. Kerr
    BMC Infectious Diseases, 22
  • [4] Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model
    Gatechompol, Sivaporn
    Sophonphan, Jiratchaya
    Ubolyam, Sasiwimol
    Avihingsanon, Anchalee
    van Leth, Frank
    Cobelens, Frank
    Kerr, Stephen J.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [5] Sexual Dysfunctions Among People Living With HIV With Long- Term Treatment With Antiretroviral Therapy
    Scanavino, Marco De Tubino
    Mori, Emi
    Nisida, Vera Vichr
    Avelino-Silva, Vivian I.
    Amaral, Maria Luiza Sant'ana do
    Messina, Bruna
    Segurado, Aluisio Cotrim
    SEXUAL MEDICINE, 2022, 10 (05)
  • [6] Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
    Ortiz, Dean W.
    Roberts-Sano, Olivia
    Marroquin, Hugo E.
    Larson, Lindsey
    Franco, Katherine B.
    Spec, Andrej
    Melendez, Johanna R.
    Pinzon, Rodolfo
    Samayoa, Ana J.
    Mejia-Chew, Carlos
    O'Halloran, Jane A.
    AIDS RESEARCH AND THERAPY, 2021, 18 (01)
  • [7] Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
    Dean W. Ortíz
    Olivia Roberts-Sano
    Hugo E. Marroquin
    Lindsey Larson
    Katherine B. Franco
    Andrej Spec
    Johanna R. Melendez
    Rodolfo Pinzón
    Ana J. Samayoa
    Carlos Mejia-Chew
    Jane A. O´Halloran
    AIDS Research and Therapy, 18
  • [8] Prevalence and factors associated with hypertension among people living with HIV/AIDS on antiretroviral therapy in Uganda
    Lubega, Gloria
    Mayanja, Billy
    Lutaakome, Joseph
    Abaasa, Andrew
    Thomson, Rebecca
    Lindan, Christina
    PAN AFRICAN MEDICAL JOURNAL, 2021, 38
  • [9] Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria
    Anyaike, Chukwuma
    Atoyebi, Oladele Ademola
    Musa, Omotoso Ibrahim
    Bolarinwa, Oladimeji Akeem
    Durowade, Kabir Adekunle
    Ogundiran, Adeniyi
    Babatunde, Oluwole Adeyemi
    PAN AFRICAN MEDICAL JOURNAL, 2019, 32
  • [10] Long-Term Trends of Coagulation Parameters in People Living With HIV Treated With Combined Antiretroviral Therapy
    Bhoelan, Soerajja
    Howard, Jaime Borjas
    Tichelaar, Vladimir
    Bierman, Wouter
    Meijer, Karina
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29